Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Goodwill & Intangibles (2016 - 2025)

Integra Lifesciences Holdings' Goodwill & Intangibles history spans 17 years, with the latest figure at $615.2 million for Q3 2025.

  • For Q3 2025, Goodwill & Intangibles fell 49.14% year-over-year to $615.2 million; the TTM value through Sep 2025 reached $615.2 million, down 49.14%, while the annual FY2024 figure was $2.3 billion, 8.54% up from the prior year.
  • Goodwill & Intangibles for Q3 2025 was $615.2 million at Integra Lifesciences Holdings, down from $1.8 billion in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $2.3 billion in Q4 2024 and bottomed at $94.1 million in Q2 2021.
  • The 5-year median for Goodwill & Intangibles is $1.2 billion (2024), against an average of $1.4 billion.
  • The largest YoY upside for Goodwill & Intangibles was 47.92% in 2025 against a maximum downside of 49.14% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $2.2 billion in 2021, then grew by 0.3% to $2.2 billion in 2022, then decreased by 1.95% to $2.1 billion in 2023, then grew by 8.54% to $2.3 billion in 2024, then tumbled by 73.3% to $615.2 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Goodwill & Intangibles are $615.2 million (Q3 2025), $1.8 billion (Q2 2025), and $2.3 billion (Q4 2024).